Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer[J]. Journal of Clinical Oncology, 2007, 25（22）：3288-3295.
[2]
Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B[J]. New England Journal of Medicine, 2004, 351（12）：1206-1217.
[3]
Liu YJ. IPC：professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors[J]. Annu Rev Immunol, 2005, 23：275-306.
[4]
Vilcek J. Novel interferons[J]. Nature Immunology, 2003, 4（1）：8-9.
[5]
Fensterl V, Sen GC. Interferons and viral infections[J]. Biofactors, 2009, 35（1）：14-20.
[6]
De Veer MJ, Holko M, Frevel M, et al. Functional classification of interferon-stimulated genes identified using microarrays[J]. Journal of Leukocyte Biology, 2001, 69（6）：912-920.
[7]
Foster GR, Finter NB. Are all type I human interferons equivalent?[J]. Journal of Viral Hepatitis, 1998, 5（3）：143-152.
[8]
Mogensen KE, Lewerenz M, Reboul J, et al. The type I interferon receptor：structure, function, and evolution of a family business[J]. Journal of Interferon & Cytokine Research, 1999, 19（10）：1069-1098.
[9]
Bell SJ, Fam CM, Chlipala EA, et al. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-α protein therapeutic[J]. Bioconjugate Chemistry, 2007, 19（1）：299-305.
[10]
Jo YW, Youn YS, Lee SH, et al. Long-acting interferon-α 2a modified with a trimer-structured polyethylene glycol：Preparation, in vitro bioactivity, in vivo stability and pharmacokinetics[J]. International Journal of Pharmaceutics, 2006, 309（1）：87-93.
[11]
Zhao HL, Yao XQ, Xue C, et al. Increasing the homogeneity, stability and activity of human serum albumin and interferon-α2b fusion protein by linker engineering[J]. Protein Expression and Purification, 2008, 61（1）：73-77.
[12]
Fioravanti J, Medina-Echeverz J, Ardaiz N, et al. The fusion protein of IFN-α and apolipoprotein AI crosses the blood-brain barrier by a saturable transport mechanism[J]. The Journal of Immunology, 2012, 188（8）：3988-3992.
[13]
Tian S, Li Q, Yao W, et al. Construction and characterization of a potent, long-lasting recombinant human serum albumin-interferon α1 fusion protein expressed in Pichia pastoris[J]. Protein Expression and Purification, 2013, 90（2）：124-128.
[14]
Hemmerle T, Neri D. The dose dependent tumor targeting of antibody-interferon gamma fusion proteins reveals an unexpected receptor trapping mechanism in vivo[J]. Cancer Immunology Research, 2014：canimm. 0182.2013.
Ceaglio N, Etcheverrigaray M, Kratje R, et al. Novel long-lasting interferon alpha derivatives designed by glycoengineering[J]. Biochimie, 2008, 90（3）：437-449.
[17]
Ke Y, Huang WQ, Li J, et al. Enzymatic characteristics of a recom-binant neutral protease I（rNpI）from Aspergillus oryzae expressed in Pichia pastoris[J]. Journal of Agricultural and Food Chemistry, 2012, 60（49）：12164-12169.
[18]
Sinclair G, Choy FYM. Synonymous codon usage bias and the expression of human glucocerebrosidase in the methylotrophic yeast Pichia pastoris[J]. Protein Expression and Purification, 2002, 26（1）：96-105.
Kanthawong S, Bolscher JGM, Veerman ECI, et al. Antimicrobial and antibiofilm activity of LL-37 and its truncated variants against Burkholderia pseudomallei[J]. International Journal of Antimic-robial Agents, 2012, 39（1）：39-44.
[22]
Wang D, Ren H, Xu JW, et al. Expression, purification and characterization of human interferon-γ in Pichia pastoris[J]. Molecular Medicine Reports, 2014, 9（2）：715-719.
[23]
Cheung RCF, Wong JH, Ng TB. Immobilized metal ion affinity chromatography：a review on its applications[J]. Applied Microbiology and Biotechnology, 2012, 96（6）：1411-1420.
[24]
Wu D, Chu J, Hao YY, et al. High efficient production of recombinant human consensus interferon mutant in high cell density culture of Pichia pastoris using two phases methanol control[J]. Process Biochemistry, 2011, 46（8）：1663-1669.
